Clinical Trial Update: Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for eflornithine (DFMO) in osteosarcoma and Ewing sarcoma (including metastatic disease) indicates the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Osteosarcoma

Drugs mentioned

• Eflornithine (DFMO) (difluoromethylornithine)

Snippet

Sponsor: Milton S. Hershey Medical Center | Conditions: Osteosarcoma, Ewing Sarcoma | Phase 2 | Status: NOT_YET_RECRUITING